ITRI Advances Ophthalmology and Cell Therapy Innovations

In an interview with GeneOnline during BIO International Convention 2025, Dr. Eric Y. Chuang from Taiwan’s Industrial Technology Research Institute (ITRI)(工業技術研究院, 工研院) highlighted two key translational research developments with significant clinical and commercial potential.

1. Ophthalmology drug candidates targeting wet AMD and glaucoma are now in Phase II clinical trials, with plans for future FDA IND submissions.
2. In the field of cell therapy, ITRI is advancing a proprietary platform based on bumpy magnetic beads designed to enhance immune cell expansion. The technology is being spun off into a new startup aimed at scaling applications for immunotherapy.